The study was made in 30 male Wistar rats (b.m. 110+/-10 g) with transplanted Guerin carcinoma to their spleen. Morphological changes in the tumour, spleen, thymus and mesenteric lymph nodes on tumour growth day 7, 10, 14, 18, 22, 25 were studied. The elaborated experimental model of tumour growth in the spleen allowed to detect tumor-specific changes in organs of immunogenesis as well as the dynamics of their development. The findings show possibility of renewal of both cellular content in the tumour-activation of proliferation, and in tissue of the spleen-blast transformation with predominance of lymphoblasts. Morphologic changes in the thymus and regional lymph nodes are different this meaning that changes in the organs of immunogenesis are not of a systemic character, their reaction to the presence of tumour in organism is not always the same and has its own features.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.
World J Urol
January 2025
Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands.
Purpose: Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1).
View Article and Find Full Text PDFOncological outcomes and prognostic implications of T1 histo-anatomic substaging in the management of high-Grade non-muscle invasive bladder cancer: results from a large single centre series.
World J Urol
December 2024
Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
Purpose: This study aimed to comprehensively evaluate the prognostic value of T1 histo-anatomic substaging (T1a/T1b) for high grade (HG) non-muscle invasive bladder cancer (NMIBC) over a large single-centre cohort.
Materials And Methods: Patients with primary HG T1 NMIBC were identified from our Institutional database, between 2011 and 2022. Data from diagnosis to repeated transurethral resection of bladder tumour (RE-TURBT), bacillus Calmette-Guérin (BCG) treatment and follow-up were collected.
FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Clin Cancer Res
December 2024
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The product represents the first approved adenoviral vector-based gene therapy and the first approved gene therapy for bladder cancer. Determination of efficacy was based on results from Study rAd-IFN-CS-003 (Study CS-003), a single-arm trial in 98 evaluable patients with BCG-unresponsive NMIBC with CIS who received intravesical instillations of the gene therapy product (75 mL of nadofaragene firadenovec at 3 × 1011 viral particles per mL) once every 3 months.
View Article and Find Full Text PDFExploring radiotherapy combined with a radiosensitizer for Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Transl Androl Urol
November 2024
Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.
Sex Disparities in Bladder Cancer Diagnosis and Treatment.
Cancers (Basel)
December 2024
Medical Oncology Unit, Centre Antoine Lacassagne, Université Côte d'Azur, 06000 Nice, France.
Gender differences in prevalence, tumor invasiveness, response to treatment, and clinical outcomes exist in different types of cancer. The aim of this article is to summarize the sex disparities in bladder cancer diagnosis and treatment and try to suggest areas for improvement. Although men are at a higher risk of developing bladder tumors, women tend to be diagnosed with more advanced stages at diagnosis and are more likely to present with upfront muscle-invasive disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!